Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022;100(1):49-55.

Assessing the validity and interpretability of the Simplified Psoriasis Index in Tunisian patients

Assessing the validity and interpretability of the Simplified Psoriasis Index in Tunisian patients

Ines Chabchoub et al. Tunis Med. 2022.

Abstract

Introduction: Multiple scores have been developed to assess the severity of psoriasis, but these scores have many limitations. The Simplified Psoriasis Index (SPI) is a summary score with separate components for current severity (SPI-s), psychosocial impact (SPI-p), and past history and interventions (SPI-i). It is available in two similar versions: proSPI and saSPI.

Aim: To assess the validity of the SPI by studying its correlation to the benchmark scores in Tunisian patients.

Methods: It was a prospective bicentric study including 80 patients with plaque psoriasis.

Results: The median PASI was 7.6 and the median DLQI was 9. The median proSPI-s was 6 and the median saSPI-s was 8. The median SPI-p was 7. The median SPI-i was 2. There was a strong correlation between the proSPI-s and PASI (r=0.87) and between the proSPI-s and saSPI-s (r=0.82). There was a medium correlation between saSPI-s and PASI (r=0.70) and between SPI-p and DLQI (r=0.67). The threshold value for proSPI-s and saSPI-s was 7.25. The threshold value for SPI-p was 6.5.

Conclusion: The SPI aims to provide a concise but global measure of the severity and impact of psoriasis on quality of life. The use of SPI has several advantages: the simplicity of use, the additional weight given to critical locations of psoriasis, the possibility for the patient to self-assess his own disease, and the possibility of evaluating all the dimensions of psoriasis at the same time.

Introduction: Plusieurs scores ont été développés permettant d’évaluer la sévérité du psoriasis. Malgré leur utilisation large, ces scores présentent de nombreuses limites. Le Simplified Psoriasis Index (SPI) est un score de sévérité qui comprend trois variables distinctes : la sévérité actuelle de la maladie (SPI-s), son impact psychosocial (SPI-p), et l’historique de la maladie psoriasique et de ses traitements (SPI-i). Le SPI est décliné en deux versions similaires : l’une est remplie par le médecin (proSPI) et la deuxième par le patient (saSPI).

Objectif : Evaluer la validité du SPI en étudiant sa corrélation aux scores de référence chez les patients tunisiens.

Méthodes :Étude prospective bi-centrique incluant 80 patients atteints de psoriasis en plaques.

Résultats : Le PASI médian était de 7,6. Le DLQI médian était de 9. Le proSPI-s médian était de 6 et le saSPI-s médian était de 8. Le SPI-p médian était de 7. Le SPI-i médian était de 2. Il existait une corrélation forte entre les scores proSPI-s et PASI (r=0,87) et entre les scores proSPI-s et saSPI-s (r=0,82). Il y’avait une corrélation moyenne entre le saSPI-s et le PASI (r=0,70) et entre le SPI-p et le DLQI (r=0,67). La valeur seuil de sévérité du proSPI-s et du saSPI-s était de 7,25. La valeur seuil de sévérité du SPI-p était de 6,5.

Conclusion : Le SPI vise à fournir une mesure concise et globale de sévérité et de l’impact du psoriasis sur la qualité de vie. L’utilisation du SPI présente plusieurs avantages : la simplicité d’utilisation, la pondération supplémentaire accordée aux localisations critiques du psoriasis sur le plan fonctionnel et psychosocial, la possibilité pour le patient de s’autoévaluer, et la possibilité d’évaluer à la fois toutes les dimensions du psoriasis.

PubMed Disclaimer

Figures

None
Figure 1: Correlation between the professional simplified psoriasis index-current severity score (proSPI-s) and the Psoriasis Area and Severity Index (PASI).
None
Figure 2. Correlation between the self-assessment simplified psoriasis index-current severity score (proSPI-s) and the Psoriasis Area and Severity Index (PASI).
None
Figure 3. Correlation between the simplified psoriasis indexpsychosocial impact score (SPI-p) and the Dermatology Life Quality Index (DLQI)
None
Figure 4. Response distribution for professional simplified psoriasis index-current severity score (proSPI-s)
None
Figure 5. Response distribution for self-assessment simplified psoriasis index-current severity score (saSPI-s)
None
Figure 6. Response distribution of the simplified psoriasis indexpsychosocial impact score (SPI-p)

Similar articles

Cited by

References

    1. Richard M A, Aractingi S, Joly P. French adaptation of a new score for global assessment of psoriasis severity: The Simplified Psoriasis Index (SPI) Ann Dermatol Venereol. 2019;146:783–92. - PubMed
    1. Finlay Andrew Yule, Khan GK_. Clinical and experimental dermatology. 3. Vol. 19. Wiley Online Library; 1994. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use; pp. 210–216. - PubMed
    1. Naldi Luigi. Clinics in dermatology. 1. Vol. 28. Elsevier; 2010. Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passé? facts and controversies; pp. 67–72. - PubMed
    1. Hsu Sylvia, Papp Kim Alexander, Lebwohl Mark G, Bagel Jerry, Blauvelt Andrew, Duffin Kristina Callis, Crowley Jeffrey, Eichenfield Lawrence F, Feldman Steven R, Fiorentino David F. Archives of dermatology. 1. Vol. 148. American Medical Association; 2012. Consensus guidelines for the management of plaque psoriasis; pp. 95–102. - PubMed
    1. Chularojanamontri Leena, Griffiths Christopher E.M., Chalmers Robert J.G. Journal of Investigative Dermatology. 8. Vol. 133. Elsevier BV; 2013. The Simplified Psoriasis Index (SPI): A Practical Tool for Assessing Psoriasis; pp. 1956–1962. - DOI - PubMed